Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Prepaid Assets (2016 - 2025)

Historic Prepaid Assets for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $7.4 million.

  • Zevra Therapeutics' Prepaid Assets rose 22504.39% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year increase of 22504.39%. This contributed to the annual value of $4.1 million for FY2024, which is 12214.91% up from last year.
  • As of Q3 2025, Zevra Therapeutics' Prepaid Assets stood at $7.4 million, which was up 22504.39% from $4.4 million recorded in Q2 2025.
  • Over the past 5 years, Zevra Therapeutics' Prepaid Assets peaked at $7.4 million during Q3 2025, and registered a low of $395000.0 during Q1 2021.
  • Its 5-year average for Prepaid Assets is $2.5 million, with a median of $2.0 million in 2021.
  • The largest annual percentage gain for Zevra Therapeutics' Prepaid Assets in the last 5 years was 23134.33% (2021), contrasted with its biggest fall of 5561.8% (2021).
  • Over the past 5 years, Zevra Therapeutics' Prepaid Assets (Quarter) stood at $1.2 million in 2021, then skyrocketed by 42.81% to $1.7 million in 2022, then rose by 8.06% to $1.8 million in 2023, then soared by 122.15% to $4.1 million in 2024, then surged by 82.58% to $7.4 million in 2025.
  • Its Prepaid Assets stands at $7.4 million for Q3 2025, versus $4.4 million for Q2 2025 and $3.8 million for Q1 2025.